New Intermountain Study Finds COVID Treatment Highly Effective in Preventing Hospitalizations, Severe Illness, and Death in Patients with Virus

In a new study, researchers from Intermountain Healthcare have found that treating high-risk COVID-19 patients with a monoclonal antibody treatment reduced severe illness and hospitalizations by more than 50 percent and saved many patients from dying due to complications from the virus. The key to effectively reducing severe illness, hospitalizations, and deaths, is that the treatment must be administered within seven days of symptom onset of COVID.

Given the documented success of the treatment, and in light of the major COVID Delta variant surge in the United States, researchers say more resources are needed to fund and expand treatment for high-risk patients.

“In a real-world application, we found that these monoclonal antibodies are as effective as clinical trial results suggested,” said the study’s lead author, Brandon Webb, MD, infectious diseases physician at Intermountain Healthcare. “Based on our findings, we recommend putting resources towards monoclonal treatment programs because they help patients avoid poor outcomes, and because they are a powerful tool to prevent overflowing hospitals.”

Given the documented success of the treatment, and in light of the major COVID Delta variant surge in the United States, researchers say more resources are needed to fund and expand treatment for high-risk patients.

“In a real-world application, we found that these monoclonal antibodies are as effective as clinical trial results suggested,” said the study’s lead author, Brandon Webb, MD, infectious diseases physician at Intermountain Healthcare. “Based on our findings, we recommend putting resources towards monoclonal treatment programs because they help patients avoid poor outcomes, and because they are a powerful tool to prevent overflowing hospitals.”

Monoclonal antibodies are a drug treatment created to mimic the body’s natural immune response to COVID-19, designed to stick to the virus’ “spike” protein and neutralize it.

Getting vaccinated against COVID-19 remains the most effective way to prevent severe disease and death. However, for patients who do contract COVID-19, especially those at high risk for complications, monoclonal antibodies are a vital tool, researchers say.

Learn more about Intermountain Healthcare on their website.